CRISPR Therapeutics (NASDAQ:CRSP) Hits New 52-Week Low – Time to Sell?

CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) shares reached a new 52-week low on Thursday. The stock traded as low as $39.50 and last traded at $40.2720, with a volume of 1,289,943 shares traded. The stock had previously closed at $40.19.

Analysts Set New Price Targets

A number of analysts have recently issued reports on CRSP shares. Piper Sandler reaffirmed an “overweight” rating and issued a $110.00 price target on shares of CRISPR Therapeutics in a research note on Tuesday, November 10th. The Goldman Sachs Group reissued a “neutral” rating and issued a $55.00 price objective on shares of CRISPR Therapeutics in a research note on Thursday, August 6th. Citigroup raised their price objective on CRISPR Therapeutics from $88.00 to $90.00 and gave the company a “buy” rating in a report on Wednesday, November 4th. Needham & Company LLC restated a “buy” rating and issued a $82.00 price objective on shares of CRISPR Therapeutics in a report on Tuesday, November 3rd. Finally, Wells Fargo & Company lowered their target price on shares of CRISPR Therapeutics from $75.00 to $70.00 and set an “equal weight” rating on the stock in a research note on Wednesday, November 4th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $72.93.

Read Our Latest Report on CRISPR Therapeutics

CRISPR Therapeutics Stock Performance

The firm’s fifty day moving average is $50.71 and its 200-day moving average is $52.23. The company has a current ratio of 16.21, a quick ratio of 16.21 and a debt-to-equity ratio of 0.36. The stock has a market capitalization of $3.80 billion, a PE ratio of -8.26 and a beta of 1.92.

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) last announced its earnings results on Monday, November 2nd. The company reported ($1.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.06) by ($0.09). CRISPR Therapeutics had a negative net margin of 1,812.07% and a negative return on equity of 25.59%. The firm had revenue of $12.67 million during the quarter, compared to analysts’ expectations of $14.75 million. CRISPR Therapeutics’s revenue for the quarter was up 1311.1% compared to the same quarter last year. As a group, research analysts anticipate that CRISPR Therapeutics AG will post -4.54 earnings per share for the current year.

Insider Buying and Selling

In other news, General Counsel James R. Kasinger sold 10,400 shares of the business’s stock in a transaction dated Tuesday, September 22nd. The stock was sold at an average price of $60.24, for a total transaction of $626,496.00. Following the completion of the transaction, the general counsel directly owned 94,784 shares of the company’s stock, valued at approximately $5,709,788.16. The trade was a 9.89% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Ali Behbahani sold 13,679 shares of CRISPR Therapeutics stock in a transaction that occurred on Thursday, September 17th. The stock was sold at an average price of $57.09, for a total transaction of $780,934.11. Following the completion of the transaction, the director owned 16,637 shares of the company’s stock, valued at $949,806.33. This represents a 45.12% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 93,558 shares of company stock worth $4,881,663. 5.20% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On CRISPR Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in CRSP. Quantinno Capital Management LP increased its position in shares of CRISPR Therapeutics by 613.5% during the first quarter. Quantinno Capital Management LP now owns 47,989 shares of the company’s stock worth $2,283,000 after purchasing an additional 41,263 shares in the last quarter. KBC Group NV lifted its holdings in shares of CRISPR Therapeutics by 3,999.9% in the 1st quarter. KBC Group NV now owns 116,847 shares of the company’s stock valued at $5,558,000 after purchasing an additional 113,997 shares during the last quarter. Raiffeisen Bank International AG acquired a new stake in shares of CRISPR Therapeutics in the 2nd quarter valued at about $1,127,000. Shah Wealth Advisors LLC acquired a new stake in shares of CRISPR Therapeutics in the 2nd quarter valued at about $3,767,000. Finally, EverSource Wealth Advisors LLC grew its stake in CRISPR Therapeutics by 56.1% during the 1st quarter. EverSource Wealth Advisors LLC now owns 89,683 shares of the company’s stock worth $4,266,000 after buying an additional 32,218 shares during the last quarter. Institutional investors and hedge funds own 69.20% of the company’s stock.

CRISPR Therapeutics Company Profile

(Get Free Report)

CRISPR Therapeutics AG is a biotechnology company focused on developing gene-based medicines using CRISPR/Cas9, a gene-editing technology that can make targeted changes to DNA. Founded in 2013, the company is headquartered in Zug, Switzerland, and maintains U.S. operations in Cambridge, Massachusetts. Its lead product, Casgevy (exa-cel), was developed with Vertex Pharmaceuticals for people with sickle cell disease and transfusion-dependent beta thalassemia. It was the first therapy based on CRISPR gene editing to receive regulatory approval.

Featured Articles

Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.